Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Chikamasa Yamashita"'
Autor:
Ryosuke Tanino, Yukari Tsubata, Takamasa Hotta, Tamio Okimoto, Yoshihiro Amano, Mayumi Takechi, Tetsuya Tanaka, Tomomi Akita, Mamiko Nagase, Chikamasa Yamashita, Koichiro Wada, Takeshi Isobe
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Emphysema limits airflow and causes irreversible progression of chronic obstructive pulmonary disease (COPD). Strain differences must be considered when selecting mouse models of COPD, owing to disease complexity. We previously reported that
Externí odkaz:
https://doaj.org/article/808c1c5d1d5947a18da3fd7110b74ed7
Autor:
Junpei Takahashi, Yudai Ueta, Daisuke Yamada, Sachie Sasaki‐Hamada, Takashi Iwai, Tomomi Akita, Chikamasa Yamashita, Akiyoshi Saitoh, Jun‐Ichiro Oka
Publikováno v:
Neuropsychopharmacology Reports, Vol 42, Iss 4, Pp 492-501 (2022)
Abstract Aim We previously reported that oxytocin, a peptide hormone, can reverse the β‐amyloid peptide (25–35) (Aβ25–35)‐induced impairments of the murine hippocampal synaptic plasticity. In this study, we examined the effects of oxytocin
Externí odkaz:
https://doaj.org/article/ff4dd2c485744413a1596cf3f380bc36
Autor:
Tomomi Akita, Kazuaki Oda, Satoru Narukawa, Yuki Morita, Kota Tange, Yuta Nakai, Chikamasa Yamashita
Publikováno v:
Pharmaceuticals, Vol 16, Iss 6, p 838 (2023)
Chronic obstructive pulmonary disease (COPD) results in obstructive ventilatory impairment caused by emphysema, and current treatment is limited to symptomatic therapy or lung transplantation. Therefore, the development of new treatments to repair al
Externí odkaz:
https://doaj.org/article/58fad632906f493a9059358d1445260e
Autor:
Tomoaki Kurosaki, Yuki Katafuchi, Junya Hashizume, Hitomi Harasawa, Hiroo Nakagawa, Mikiro Nakashima, Tadahiro Nakamura, Chikamasa Yamashita, Hitoshi Sasaki, Yukinobu Kodama
Publikováno v:
Drug Delivery, Vol 28, Iss 1, Pp 1585-1593 (2021)
We previously found that a nanoparticle constructed with an antigen, benzalkonium chloride (BK) and γ-polyglutamic acid (γ-PGA) showed high Th1 and Th2-type immune induction after subcutaneous administration. For prophylaxis of respiratory infectio
Externí odkaz:
https://doaj.org/article/1ae04cee4a2a4aa4a42fa110b05051e5
Autor:
Tomomi Akita, Yuki Morita, Takehiro Kawai, Kazuaki Oda, Kota Tange, Yuta Nakai, Chikamasa Yamashita
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 37 (2022)
Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis and emphysema, and current drug treatments target its symptoms. Thus, the development of a therapeutic drug to repair alveolar destruction is urgently needed. Our pre
Externí odkaz:
https://doaj.org/article/daaa5c829bf14b0684fdbad55111dad2
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 759 (2022)
Human lung deposition data is non-mandatory for drug approval but very useful for the development of orally inhaled drug products. Lung deposition of inhaled drugs can be quantified by radionuclide imaging, for which one of the first considerations i
Externí odkaz:
https://doaj.org/article/8d477b4c355c46d69a4cc39e0097cf25
Autor:
Kentaro Ushijima, Chisato Suzuki, Hiroko Kitamura, Ken Shimada, Hirotoshi Kawata, Akira Tanaka, Hisanaga Horie, Yoshinori Hosoya, Chikamasa Yamashita, Akio Fujimura
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 8, Iss 1 (2020)
Introduction We previously reported in ob/ob mice, one of animal models of human type 2 diabetes mellitus (DM2), that (i) acetylation of histone H3 lysine 9 (H3K9) at the promoter region of clock gene Dbp and DBP mRNA expression are reduced in epidid
Externí odkaz:
https://doaj.org/article/9de6567e6633492fa9f4ab063b30a1ec
Autor:
Kahori Miyamoto, Misato Yanagisawa, Hiroaki Taga, Hiromichi Yamaji, Tomomi Akita, Chikamasa Yamashita
Publikováno v:
Pharmaceutics, Vol 13, Iss 5, p 632 (2021)
It has been previously reported that active vitamin D3 (VD3) is a candidate drug that can repair alveolar damage in chronic obstructive pulmonary disease at a very low dose. We herein report the optimization of a very low-dose formulation of VD3 for
Externí odkaz:
https://doaj.org/article/5a7a5b3510c24ea29f4cebfda721da7b
Autor:
Yuki Fujiwara, Hitoshi Ando, Kentaro Ushijima, Michiko Horiguchi, Chikamasa Yamashita, Akio Fujimura
Publikováno v:
Journal of Pharmacological Sciences, Vol 134, Iss 4, Pp 234-238 (2017)
The anticoagulant effect of rivaroxaban, a direct inhibitor of activated factor X (FX), might be influenced by its dosing time because the activity of the coagulofibrinolytic system exhibits daily rhythmicity. In rats, FX activity follows a 24-h rhyt
Externí odkaz:
https://doaj.org/article/27dcb56b97e44babba03d6e9f6b41972
Systemic Delivery of hGhrelin Derivative by Lyophilizate for Dry Powder Inhalation System in Monkeys
Publikováno v:
Pharmaceutics, Vol 13, Iss 2, p 233 (2021)
Ghrelin is the peptide that increases the hunger sensation and food intake and is expected to be clinically applied for treatment of diseases such as cachexia and anorexia nervosa. In the clinical application of ghrelin, injections are problematic in
Externí odkaz:
https://doaj.org/article/d597dd7a57df468fb0ddd6fb331325cf